Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
ALZN Alzamend Neuro
1.080
-0.005-0.46%
YOY
Do not show
Hide blank lines
(Q1)2022/07/31(FY)2022/04/30(Q4)2022/04/30(Q3)2022/01/31
Assets
Current assets
Cash, cash equivalents and short term investments
-26.19% 11.53M 628.97% 14.06M 628.97% 14.06M 28842.46% 11.79M
-Cash and cash equivalents
-26.19% 11.53M 628.97% 14.06M 628.97% 14.06M 28842.46% 11.79M
Receivables
-41.93% 9.41K -- 0 -- 0 -- 0
-Other receivables
-41.93% 9.41K -- -- -- -- -- --
Prepaid assets
-51.14% 578.13K -43.1% 349.72K -43.1% 349.72K -14.26% 638.83K
Total current assets
-27.96% 12.11M 394.87% 14.41M 394.87% 14.41M 1449.75% 12.43M
Non current assets
Net PPE
-- 95.81K -- 102.91K -- 102.91K -- --
Total non current assets
-- 95.81K -- 102.91K -- 102.91K -- 0
Total assets
-27.39% 12.21M 398.4% 14.52M 398.4% 14.52M 1449.75% 12.43M
Liabilities
Current liabilities
Payables
-9.23% 1.03M 106.42% 1.16M 106.42% 1.16M -73.18% 466.98K
-accounts payable
-4.09% 1.03M 130.91% 1.16M 130.91% 1.16M -46.99% 464.9K
-Due to related parties current
-- 0 -96.57% 2.08K -96.57% 2.08K -99.76% 2.08K
Current liabilities
-30.18% 1.03M 29.49% 1.16M 29.49% 1.16M -77.74% 466.98K
Non current liabilities
Total non current liabilities
-- 0 -- 0 -- 0 -- 0
Total liabilities
-30.18% 1.03M 29.49% 1.16M 29.49% 1.16M -77.74% 466.98K
Shareholders'equity
Share capital
9.89% 9.55K 40.04% 9.55K 40.04% 9.55K 37.54% 9.01K
-common stock
9.89% 9.55K 41.6% 9.55K 41.6% 9.55K 39.13% 9.01K
-Preferred stock
-- 0 -- 0 -- 0 -- 0
Retained earnings
-68.29% -32.23M -73.44% -29.19M -73.44% -29.19M -62.59% -25.33M
Paid-in capital
18.06% 58.29M 70.27% 57.42M 70.27% 57.42M 78.9% 52.16M
Other equity interest
0% -14.88M 0% -14.88M 0% -14.88M 0% -14.88M
Total stockholders'equity
-27.13% 11.18M 563.28% 13.35M 563.28% 13.35M 1023.04% 11.96M
Total equity
-27.13% 11.18M 563.28% 13.35M 563.28% 13.35M 1023.04% 11.96M
Currency Unit
USDUSDUSDUSD
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company, which engages in the manufacture of pharmaceutical products. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.
CEO: Mr. Stephan Jackman
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...